购物车
全部删除
您的购物车当前为空
别名 Curaxin 137, CBLC137
CBL0137 (Curaxin 137) 是一种代谢稳定的 curaxin,可激活 p53 (EC50: 0.37 μM) 并抑制 NF-κB (EC50: 0.47 μM)。它在功能上使促进染色质转录复合物 (FACT) 失活,从而驱动对 p53 和 NF-κB 的影响并促进癌细胞死亡。口服 CBL0137 在小鼠体内具有广泛的抗癌活性,可根除耐药性癌症干细胞,并增强吉西他滨在胰腺癌临床前模型中的疗效。

CBL0137 (Curaxin 137) 是一种代谢稳定的 curaxin,可激活 p53 (EC50: 0.37 μM) 并抑制 NF-κB (EC50: 0.47 μM)。它在功能上使促进染色质转录复合物 (FACT) 失活,从而驱动对 p53 和 NF-κB 的影响并促进癌细胞死亡。口服 CBL0137 在小鼠体内具有广泛的抗癌活性,可根除耐药性癌症干细胞,并增强吉西他滨在胰腺癌临床前模型中的疗效。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 343 | 现货 | |
| 5 mg | ¥ 993 | 现货 | |
| 10 mg | ¥ 1,570 | 现货 | |
| 25 mg | ¥ 2,830 | 现货 | |
| 50 mg | ¥ 4,250 | 现货 | |
| 100 mg | ¥ 5,910 | 现货 | |
| 1 mL x 10 mM (in DMSO) | ¥ 919 | 现货 |
CBL0137 相关产品
| 产品描述 | CBL0137 (Curaxin 137), a metabolically stable curaxin, activates p53 (EC50: 0.37 μM) and inhibits NF-κB (EC50: 0.47 μM). It functionally inactivates the facilitates chromatin transcription complex (FACT), driving the effects on p53 and NF-κB and promoting cancer cell death. CBL0137 has broad anticancer activity in mice when administered orally, eradicates drug-resistant cancer stem cells, and potentiates the efficacy of gemcitabine in preClinicalal models of pancreatic cancer. |
| 靶点活性 | NF-κB:0.47 μM (EC50), p53:0.37 μM (EC50) |
| 别名 | Curaxin 137, CBLC137 |
| 分子量 | 336.43 |
| 分子式 | C21H24N2O2 |
| CAS No. | 1197996-80-7 |
| Smiles | C(CNC(C)C)N1C=2C(C=3C1=CC=C(C(C)=O)C3)=CC(C(C)=O)=CC2 |
| 密度 | no data available |
| 颜色 | White |
| 物理性状 | Solid |
| 存储 | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 25 mg/mL (74.31 mM), Sonication is recommended. H2O: Insoluble | ||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.94 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
评论内容